Accordingly, before attending the first visit at the NPD outpatient service, only 25.5% and 21.8% of our DKD population was already treated with SGLT-2 inhibitors and/or GLP-1R agonists, respectively (Table 2). Here, SLC5A2 is linked to diabetic kidney disease.